103-LB: Intergenerational Improvements of Continuous Glucose Monitoring Systems in Youth

Abstract

Standard methods and metrics to describe the accuracy of continuous glucose monitoring (CGM) systems in children and adolescents are subject to change. We reanalyzed data from youth ages 6-17 from clinical trials evaluating G4 PLATINUM (NCT01667185), G5 Mobile (NCT02280577), and G6 (NCT02880267) CGM systems (all from Dexcom, Inc., San Diego, CA). Subjects participated in 1-2 clinic sessions of varying duration, depending on their age, throughout the 7-day wear of G4 and G5 and 10-day wear of G6 for comparison of CGM values with temporally matched YSI measurements. Reference measurements were obtained every 15±5 minutes and paired with the CGM measurement that immediately followed (within 5 minutes). Percent accuracy was defined as the proportion of CGM values within ±20% of paired YSI values for CGM values >100 mg/dL or within ±20 mg/dL of paired YSI values for CGM values ≤100 mg/dL. Accuracy was also evaluated using the mean absolute difference (MAD) and mean absolute relative difference (MARD) between CGM and YSI pairs, as well as the proportion of pairs in Clarke Error Grid (CEG) Zone A. Accuracy improved dramatically from G4 to G6, regardless of the metric evaluated (Table). Improved device performance may drive increased uptake and adherence, especially among children and adolescents. Disclosure S. Puhr: Employee; Self; Dexcom, Inc. P. Calhoun: Stock/Shareholder; Self; Dexcom, Inc. J. Welsh: Employee; Self; Dexcom, Inc. T.C. Walker: Employee; Self; Dexcom, Inc. D.A. Price: Employee; Self; Dexcom, Inc. Stock/Shareholder; Self; Johnson & Johnson.